Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
Optical, structural and thermal properties of sodium metaphosphate glasses containing Bi.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Marzouk MA, ElBatal FH, ElBadry KM, ElBatal HA.
PMID: 27588953
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jan 15;171:454-460. doi: 10.1016/j.saa.2016.08.038. Epub 2016 Aug 23.

Sodium metaphosphate glasses with successive increasing added Bi

Cite
Marzouk MA, ElBatal FH, ElBadry KM, et al. Optical, structural and thermal properties of sodium metaphosphate glasses containing Bi. Spectrochim Acta A Mol Biomol Spectrosc. 2016;171:454-460doi: 10.1016/j.saa.2016.08.038.
Marzouk, M. A., ElBatal, F. H., ElBadry, K. M., & ElBatal, H. A. (2017). Optical, structural and thermal properties of sodium metaphosphate glasses containing Bi. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 171454-460. https://doi.org/10.1016/j.saa.2016.08.038
Marzouk, M A, et al. "Optical, structural and thermal properties of sodium metaphosphate glasses containing Bi." Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy vol. 171 (2017): 454-460. doi: https://doi.org/10.1016/j.saa.2016.08.038
Marzouk MA, ElBatal FH, ElBadry KM, ElBatal HA. Optical, structural and thermal properties of sodium metaphosphate glasses containing Bi. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jan 15;171:454-460. doi: 10.1016/j.saa.2016.08.038. Epub 2016 Aug 23. PMID: 27588953.
Copy Download .nbib Format: NLM
The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.

Microbial pathogenesis

Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK.
PMID: 34843922
Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26.

Hepatitis C virus (HCV) is the leading cause of liver diseases worldwide. At present, combinations of different classes of direct-acting antiviral agents (DAAs) are used as treatment options for HCV, in which sofosbuvir (SOF) is the common DAA among...

Cite
Ibrahim MK, AbdElrahman M, Bader El Din NG, et al. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021;162:105311doi: 10.1016/j.micpath.2021.105311.
Ibrahim, M. K., AbdElrahman, M., Bader El Din, N. G., Tawfik, S., Abd-Elsalam, S., Omran, D., Barakat, A. Z., Farouk, S., Elbatae, H., & El Awady, M. K. (2021). The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial pathogenesis, 162105311. https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim, Marwa K, et al. "The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients." Microbial pathogenesis vol. 162 (2021): 105311. doi: https://doi.org/10.1016/j.micpath.2021.105311
Ibrahim MK, AbdElrahman M, Bader El Din NG, Tawfik S, Abd-Elsalam S, Omran D, Barakat AZ, Farouk S, Elbatae H, El Awady MK. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microb Pathog. 2021 Nov 26;162:105311. doi: 10.1016/j.micpath.2021.105311. Epub 2021 Nov 26. PMID: 34843922.
Copy Download .nbib Format: NLM
The Truncated Burr X-G Family of Distributions: Properties and Applications to Actuarial and Financial Data.

Entropy (Basel, Switzerland)

Bantan RAR, Chesneau C, Jamal F, Elbatal I, Elgarhy M.
PMID: 34441228
Entropy (Basel). 2021 Aug 21;23(8). doi: 10.3390/e23081088.

In this article, the "truncated-composed" scheme was applied to the Burr X distribution to motivate a new family of univariate continuous-type distributions, called the truncated Burr X generated family. It is mathematically simple and provides more modeling freedom for...

Cite
Bantan RAR, Chesneau C, Jamal F, et al. The Truncated Burr X-G Family of Distributions: Properties and Applications to Actuarial and Financial Data. Entropy (Basel). 2021;23(8)doi: 10.3390/e23081088.
Bantan, R. A. R., Chesneau, C., Jamal, F., Elbatal, I., & Elgarhy, M. (2021). The Truncated Burr X-G Family of Distributions: Properties and Applications to Actuarial and Financial Data. Entropy (Basel, Switzerland), 23(8), . https://doi.org/10.3390/e23081088
Bantan, Rashad A R, et al. "The Truncated Burr X-G Family of Distributions: Properties and Applications to Actuarial and Financial Data." Entropy (Basel, Switzerland) vol. 23,8 (2021). doi: https://doi.org/10.3390/e23081088
Bantan RAR, Chesneau C, Jamal F, Elbatal I, Elgarhy M. The Truncated Burr X-G Family of Distributions: Properties and Applications to Actuarial and Financial Data. Entropy (Basel). 2021 Aug 21;23(8). doi: 10.3390/e23081088. PMID: 34441228; PMCID: PMC8391697.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries